Compare Stocks: HOWL, IPHA, PRQR, and ORGO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.92 -0.9%	$0.76	$0.27 ▼ $2.13	$45.20M	0.51	692,905 shs	278,151 shs
IPHA Innate Pharma	$1.59 +0.6%	$1.95	$1.17 ▼ $2.71	$176.52M	0.72	60,739 shs	133,729 shs
ORGO Organogenesis	$1.34 +3.9%	$1.71	$1.28 ▼ $7.08	$165.99M	1.27	679,566 shs	608,728 shs
PRQR ProQR Therapeutics	$1.65 -1.2%	$1.93	$1.33 ▼ $3.10	$175.96M	0.2	678,944 shs	504,585 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	-0.86%	+1.32%	-4.58%	+156.25%	-54.58%
IPHA Innate Pharma	+0.63%	-0.63%	-23.56%	-13.59%	-20.70%
ORGO Organogenesis	+3.88%	-3.25%	-21.64%	-45.75%	-68.10%
PRQR ProQR Therapeutics	-1.20%	0.00%	-20.29%	-1.79%	-30.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$0.92 -0.9%	$0.76	$0.27 ▼ $2.13	$45.20M	0.51	692,905 shs	278,151 shs
IPHA Innate Pharma	$1.59 +0.6%	$1.95	$1.17 ▼ $2.71	$176.52M	0.72	60,739 shs	133,729 shs
ORGO Organogenesis	$1.34 +3.9%	$1.71	$1.28 ▼ $7.08	$165.99M	1.27	679,566 shs	608,728 shs
PRQR ProQR Therapeutics	$1.65 -1.2%	$1.93	$1.33 ▼ $3.10	$175.96M	0.2	678,944 shs	504,585 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	-0.86%	+1.32%	-4.58%	+156.25%	-54.58%
IPHA Innate Pharma	+0.63%	-0.63%	-23.56%	-13.59%	-20.70%
ORGO Organogenesis	+3.88%	-3.25%	-21.64%	-45.75%	-68.10%
PRQR ProQR Therapeutics	-1.20%	0.00%	-20.29%	-1.79%	-30.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	333.84% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	319.29% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	223.38% Upside
PRQR ProQR Therapeutics	2.63	Moderate Buy	$7.60	360.61% Upside

Current Analyst Ratings Breakdown

Latest HOWL, IPHA, PRQR, and ORGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	PRQR ProQR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/1/2026	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
10/1/2026	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
9/22/2026	IPHA Innate Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/10/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/20/2026	PRQR ProQR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOWL Werewolf Therapeutics	$1.88M	23.83	N/A	N/A	$0.51 per share	1.81
IPHA Innate Pharma	$10.19M	17.43	N/A	N/A	($0.26) per share	-6.12
ORGO Organogenesis	$564.17M	0.31	$0.67 per share	1.99	$2.36 per share	0.57
PRQR ProQR Therapeutics	$17.99M	9.66	N/A	N/A	$0.53 per share	3.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
PRQR ProQR Therapeutics	-$47.73M	-$0.46	N/A	N/A	N/A	-223.51%	-73.83%	-35.14%	11/5/2026 (Estimated)

Latest HOWL, IPHA, PRQR, and ORGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	HOWL Werewolf Therapeutics	-$0.22	N/A	N/A	N/A	$18.31 million	N/A
8/13/2026	Q2 2026	PRQR ProQR Therapeutics	-$0.1303	-$0.0914	+$0.0389	-$0.09	$4.56 million	$10.00 million
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOWL Werewolf Therapeutics	N/A	2.91	2.91
IPHA Innate Pharma	N/A	0.60	N/A
ORGO Organogenesis	0.07	3.52	3.00
PRQR ProQR Therapeutics	N/A	3.49	3.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOWL Werewolf Therapeutics	64.84%
IPHA Innate Pharma	0.16%
ORGO Organogenesis	49.57%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
HOWL Werewolf Therapeutics	23.60%
IPHA Innate Pharma	31.89%
ORGO Organogenesis	18.80%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOWL Werewolf Therapeutics	14	48.60 million	37.13 million	Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable
PRQR ProQR Therapeutics	166	105.36 million	96.51 million	Optionable

HOWL, IPHA, PRQR, and ORGO Headlines

Recent News About These Companies

HC Wainwright Has Negative Estimate for PRQR FY2028 Earnings

October 5 at 1:29 AM | americanbankingnews.com

FY2028 Earnings Estimate for PRQR Issued By HC Wainwright

October 5 at 1:26 AM | marketbeat.com

Beam Therapeutics (NASDAQ:BEAM) and ProQR Therapeutics (NASDAQ:PRQR) Critical Contrast

October 4 at 4:15 AM | americanbankingnews.com

Chardan Capital Reaffirms "Buy" Rating for ProQR Therapeutics (NASDAQ:PRQR)

October 3, 2026 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Cut by HC Wainwright

October 3, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)

October 2, 2026 | theglobeandmail.com

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

October 2, 2026 | marketbeat.com

ProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan Capital

October 1, 2026 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Lowered at HC Wainwright

October 1, 2026 | marketbeat.com

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

September 23, 2026 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages

September 23, 2026 | marketbeat.com

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

September 10, 2026 | finance.yahoo.com

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

September 9, 2026 | globenewswire.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Should You Sell?

September 9, 2026 | marketbeat.com

ProQR to Participate in Upcoming Investor Conferences in September 2026

September 2, 2026 | globenewswire.com

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

August 21, 2026 | seekingalpha.com

ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results

August 15, 2026 | theglobeandmail.com

ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation

August 15, 2026 | theglobeandmail.com

ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones

August 13, 2026 | quiverquant.comQ

ProQR Announces Second Quarter 2026 Operating and Financial Results

August 13, 2026 | globenewswire.com

Bart Filius Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

July 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, IPHA, PRQR, and ORGO Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

$0.92 -0.01 (-0.86%)

Closing price 10/6/2026 03:59 PM Eastern

Extended Trading

$0.91 -0.01 (-1.30%)

As of 05:33 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Innate Pharma NASDAQ:IPHA

$1.59 +0.01 (+0.63%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.31%)

As of 10/6/2026 04:10 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Organogenesis NASDAQ:ORGO

$1.34 +0.05 (+3.88%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$1.33 -0.01 (-0.75%)

As of 05:47 AM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ProQR Therapeutics NASDAQ:PRQR

$1.65 -0.02 (-1.20%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$1.65 0.00 (-0.06%)

As of 04:44 AM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, IPHA, PRQR, and ORGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, IPHA, PRQR, and ORGO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, IPHA, PRQR, and ORGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, IPHA, PRQR, and ORGO Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

Innate Pharma NASDAQ:IPHA

Organogenesis NASDAQ:ORGO

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, IPHA, PRQR, and ORGO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, IPHA, PRQR, and ORGO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, IPHA, PRQR, and ORGO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, IPHA, PRQR, and ORGO Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

Innate Pharma NASDAQ:IPHA

Organogenesis NASDAQ:ORGO

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools